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A B S T R A C T
Purpose
To provide current recommendations about the prophylaxis and treatment of venous thromboem-
bolism (VTE) in patients with cancer.
Methods
PubMed and the Cochrane Library were searched for randomized controlled trials, systematic
reviews, meta-analyses, and clinical practice guidelines from November 2012 through July 2014.
An update committee reviewed the identified abstracts.
Results
Of the 53 publications identified and reviewed, none prompted a change in the
2013 recommendations.
Recommendations
Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitaliza-
tion. Routine thromboprophylaxis is not recommended for patients with cancer in the outpatient
setting. It may be considered for selected high-risk patients. Patients with multiple myeloma
receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should receive
prophylaxis with either low–molecular weight heparin (LMWH) or low-dose aspirin. Patients
undergoing major surgery should receive prophylaxis starting before surgery and continuing for at
least 7 to 10 days. Extending prophylaxis up to 4 weeks should be considered in those undergoing
major abdominal or pelvic surgery with high-risk features. LMWH is recommended for the initial
5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as for
long-term secondary prophylaxis (at least 6 months). Use of novel oral anticoagulants is not
currently recommended for patients with malignancy and VTE because of limited data in patients
with cancer. Anticoagulation should not be used to extend survival of patients with cancer in the
absence of other indications. Patients with cancer should be periodically assessed for VTE risk.
Oncology professionals should educate patients about the signs and symptoms of VTE.
J Clin Oncol 33:654-656. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The goal of this 2014 guideline update is to provide
oncologists and other clinicians with current rec-
ommendations regarding the prevention and
treatment of venous thromboembolism (VTE) in
patients with cancer. The American Society of
Clinical Oncology (ASCO) first published an
evidence-based clinical practice guideline on VTE
in patients with cancer in 2007, with an updated
guideline published in 2013.1 The current 2014
update assesses whether the 2013 recommendations
remain valid. A complete list of previous recommen-
dations is available at www.asco.org/guidelines/vte and
in Data Supplement 1.
METHODS
Guideline Update Process
PubMed and the Cochrane Library were
searched for randomized controlled trials, systematic
reviews, meta-analyses, and clinical practice guide-
lines for the period from November 5, 2012, through
July 2014. The disease and intervention search terms
were those that were used for the 2013 guideline
update. An update committee (members listed in
Appendix Table A1, online only), formed in accordance
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with the ASCO Conflict of Interest Management Procedures for Clinical
Practice Guidelines, reviewed the abstracts that were identified for predefined
signals that would suggest the need to change a previous recommendation. Addi-
tional information about the results of the updated literature search (Data Supple-
ment 2) and 2014 search strategy string and results (Data Supplement 3), as well as
a discussion of the ASCO signals approach to guideline updating, are avail-
able at www.asco.org/guidelines/vte and in the 2014 Data Supplement and
2014 Methodology Supplement, respectively. A QUOROM diagram of the up-
dated search and the clinical questions are provided in Data Supplements 4 and 5,
respectively.
THE BOTTOM LINE
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● Medical oncologists, surgical oncologists, hospitalists, oncology nurses
Key Recommendations
● Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization. Data are
inadequate to support routine thromboprophylaxis in patients admitted for minor procedures or short
chemotherapy infusion.
● Routine thromboprophylaxis is not recommended for ambulatory patients with cancer. It may be considered for highly
select high-risk patients.
● Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should
receive prophylaxis with either low–molecular weight heparin (LMWH) or low-dose aspirin to prevent venous
thromboembolism (VTE).
● Patients undergoing major cancer surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 days.
● Extending postoperative prophylaxis up to 4 weeks should be considered in those undergoing major abdominal or pelvic
surgery with high-risk features.
● LMWH is recommended for the initial 5 to 10 days of treatment of established deep vein thrombosis and pulmonary
embolism as well as for long-term secondary prophylaxis for at least 6 months.
● Use of novel oral anticoagulants is not currently recommended for patients with malignancy and VTE.
● Anticoagulation should not be used to extend survival of patients with cancer in the absence of other indications.
● Patients with cancer should be periodically assessed for VTE risk.
● Oncology professionals should educate patients about the signs and symptoms of VTE.
Methods
● An update committee was convened to determine whether previous recommendations remain valid based on an updated
review of evidence from the medical literature.
Additional Information
● This guideline is published in Journal of Clinical Oncology. Data Supplements, including evidence tables, and clinical tools
and resources can be found at www.asco.org/guidelines/vte.
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Guideline Disclaimer
The clinical practice guideline and other guidance published herein are
provided by ASCO to assist providers in clinical decision making. The infor-
mation herein should not be relied on as being complete or accurate, nor
should it be considered as inclusive of all proper treatments or methods of care
or as a statement of the standard of care. With the rapid development of
scientific knowledge, new evidence may emerge between the time information
is developed and when it is published or read. The information is not contin-
ually updated and may not reflect the most recent evidence. The information
addresses only the topics specifically identified therein and is not applicable to
other interventions, diseases, or stages of diseases. This information does not
mandate any particular course of medical care. Furthermore, the information
is not intended to substitute for the independent professional judgment of the
treating provider, because the information does not account for individual
variation among patients. Recommendations reflect high, moderate, or low
confidence in the net effect of a given course of action. The use of words such
as “must,” “must not,” “should,” and “should not” indicates that a course of
action is recommended or not recommended for either most or many pa-
tients, but there is latitude for the treating physician to select other courses of
action in individual cases. In all cases, the selected course of action should be
considered by the treating provider in the context of treating the individual
patient. Use of the information is voluntary. ASCO provides this information
on an as-is basis and makes no warranty, express or implied, regarding the
information. ASCO specifically disclaims any warranties of merchantability or
fitness for a particular use or purpose. ASCO assumes no responsibility for any
injury or damage to persons or property arising out of or related to any use of
this information or for any errors or omissions.
This is the most recent information as of the publication date. For the
most recent information, or to submit new evidence, please visit www.asco
.org/guidelines/vte and the ASCO guidelines wiki at www.asco.org/
guidelineswiki.
Guideline and Conflicts of Interest
The update committee was assembled in accordance with the ASCO
Conflict of Interest Management Procedures for Clinical Practice Guidelines
(summarized at http://www.asco.org/rwc). Members of the committee com-
pleted the ASCO disclosure form, which requires disclosure of financial and
other interests that are relevant to the subject matter of the guideline, including
relationships with commercial entities that are reasonably likely to experience
direct regulatory or commercial impact as a result of promulgation of the
guideline. Categories for disclosure include employment relationships, con-
sulting arrangements, stock ownership, honoraria, research funding, and ex-
pert testimony. In accordance with these procedures, the majority of the
members of the committee did not disclose any such relationships.
RESULTS
The search yielded 53 publications. After careful review of the identi-
fied publications, the update committee concluded that there were no
results that would change the 2013 guideline recommendations.1 A
bibliography of the results of the updated literature search is provided
in Data Supplement 2.
RECOMMENDATIONS
The 2014 recommendations are listed in the Bottom Line Box.
These recommendations are consistent with the previous
(2013) recommendations.
ASCO believes that cancer clinical trials are vital to inform med-
ical decisions and improve cancer care and that all patients should
have the opportunity to participate.
ADDITIONAL RESOURCES
More information, including Data and Methodology Supplements,
slide sets, and clinical tools and resources, is available at www.asco.org/
guidelines/vte. Patient information is available at www.cancer.net.
Visit www.asco.org/guidelineswiki to provide comments on the
guideline or to submit new evidence.
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Appendix
Table A1. ASCO Update Committee Members
Member Affiliation
Anna Falanga, MD (co-chair) Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
Gary H. Lyman, MD, MPH (co-chair) Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
Alok A. Khorana, MD Cleveland Clinic, Cleveland, OH
Nicole M. Kuderer, MD University of Washington, Seattle, WA
Juan Ignacio Arcelus, MD, PhD Department of Surgery, Hospital Universitario Virgen de las Nieves, University of Granada, Granada, Spain
Edward P. Balaban, DO (PGIN representative) Cancer Care Partnership, Mount Nittany Health and Penn State Hershey Cancer Institute, State College,
PA
Jeffrey M. Clarke, MD Duke University Medical Center, Durham, NC
Christopher R. Flowers, MD, MS Emory University School of Medicine, Atlanta, GA
Charles W. Francis, MD James P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY
Leigh E. Gates, BA, CPHQ (patient representative) Denver, CO
Ajay K. Kakkar, MD, BS, PhD Thrombosis Research Institute, London, United Kingdom
Nigel S. Key, MB, ChB, FRCP Division of Hematology/Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC
Agnes Y. Lee, MD, MSc, FRCPC University of British Columbia, Vancouver, British Columbia, Canada
Mark N. Levine, MD, MSc Department of Oncology, McMaster University, Hamilton, Ontario, Canada
Howard A. Liebman, MD University of Southern California, Keck School of Medicine, Jane Anne Nohl Division of Hematology,
Department of Medicine and Norris Comprehensive Cancer Center, Los Angeles, CA
Margaret A. Tempero, MD University of California San Francisco Pancreas Center, San Francisco, CA
Sandra L. Wong, MD Department of Surgery, University of Michigan, Ann Arbor, MI
NOTE. ASCO staff: Kari Bohlke, ScD, and Mark R. Somerfield, PhD.
Abbreviations: ASCO, American Society of Clinical Oncology; PGIN, Practice Guidelines Implementation Network.
Steering committee member.
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